Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05888792

Myopia Control Efficacy of Second-generation DIMS Spectacle Lenses on Fast Progressing Myopes

The purpose of this study is to examine the efficacy and performance of the variant of Defocus Incorporated Spectacle lenses on controlling myopia progression in fast progressing myopic children.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

4 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

School of Optometry, The Hong Kong Polytechnic University

Hung Hom, Hong Kong

About this study

The variant of Defocus Incorporated Spectacle lenses (D2) is a multifocal spectacle lens that produces myopic defocus images and corrects distance refractive errors at the same time.

Participants will be randomly allocated to either single vision lens group (control) or the variant of Defocus Incorporated Spectacle lens (D2) group (treatment). After 12 months of lens wear, the SV lens prescribed to the control group will be replaced with the D2 lens and be monitored for another 36 months. In parallel, the D2 treatment groups will continue their corresponding intervention for another 36 months. Their cycloplegic refraction and axial length will be monitored every 6 months over 4 years. The changes in refractive errors and axial length in two groups will be compared.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • SER: -0.75D or below in both eyes
  • Documented history of fast progressing myopia, either in SER or AL
  • SER progression: 0.50D/year or more
  • AL elongation: 0.27mm/year or more
  • For children aged 4-6 years without past prescription forms,
  • 4-5 years old: myopia of -0.75D or below in both eyes
  • 6 years old: myopia of -1.25D or below in at least one eye, with the other eye -0.75D or below
  • Best-corrected visual acuity (VA) in both eyes:
  • 4 - 6 years old: 0.20 logMAR (or its equivalent) or better
  • 7-12 years old: 0.00 logMAR (or its equivalent) or better
  • Acceptance of random group allocation and the masked study design
  • Anisometropia of 1.50 D or less
  • Astigmatism of 2.00 D or less

Exclusion criteria

  • Strabismus and binocular vision abnormalities
  • Ocular and systemic abnormalities
  • Prior experience of myopia control

Treatment and study plan

Variant of Defocus Incorporated Spectacle lens (DG2)

Other

DG2 is a variant of Defocus Incorporated Spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously

Primary outcomes

  1. Cycloplegic refraction change in spherical equivalent refraction (SER)

    Time frame: Baseline, every 6 months for 4 years

    Cycloplegic SER (in diopter) will be measured using an open field autorefractor.

    Change in SER with cycloplegia from the baseline every 6 months for 4 years over the study period.

Secondary outcomes

  1. Axial length change

    Time frame: Baseline, every 6 months for 4 years

    Axial length (mm) will be measured after cycloplegia using a non-contact optical biometer.

    Change in axial length from the baseline every 6 months for 4 years over the study period.

Sponsors and collaborators

Lead sponsor

The Hong Kong Polytechnic University

Other

Collaborators

  • HOYA Lens Thailand LTD.

Registry information

Official study title

Myopia Control Effectiveness of Second-generation Defocus Incorporated Multiple Segments Spectacle Lenses on Fast Progressing Myopes: A Randomized Controlled Trial

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Jun 5, 2023
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.